These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36405741)

  • 1. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
    Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
    Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
    Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
    BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
    Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
    Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
    Fang Q; Chen H
    Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment.
    Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M
    J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
    Li Z; Li F; Peng Y; Fang J; Zhou J
    Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An N
    Song D; Tian Y; Luo J; Shao G; Zheng J
    Ann Transl Med; 2022 Apr; 10(8):464. PubMed ID: 35571429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
    Wu X; Zhang X; Tao L; Dai X; Chen P
    Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.
    Zhu XL; Li Q; Shen J; Shan L; Zuo ED; Cheng X
    Transl Cancer Res; 2021 Dec; 10(12):5337-5351. PubMed ID: 35116381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.
    Xie H; Shi M; Liu Y; Cheng C; Song L; Ding Z; Jin H; Cui X; Wang Y; Yao D; Wang P; Yao M; Zhang H
    Front Immunol; 2022; 13():914977. PubMed ID: 36032107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of m
    Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z
    J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.